在瘤患者中,ifosfamide诱导的毒性
Juan Eduardo Quiroz-Aldave1, María Del Carmen Durand-Vásquez1, Freddy Shanner Chávez-Vásquez2
1Division of Non-communicable diseases, Endocrinology research line, Hospital de Apoyo Chepén, Chepén, Perú.
Expert review of anticancer therapy
|November 30, 2023
概括
伊福斯法米德化疗可能会因为有毒代谢物而导致脏损伤. 虽然补水和尿液有帮助,但仍然需要有效的预防策略来预防ifosfamide诱导的毒性.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊福斯法米德是一种重要的基化疗剂,用于治疗各种瘤.
- 对伊福斯法米德的主要担忧是它可能导致严重的损伤 (毒性).
研究的目的:
- 审查ifosfamide诱导的毒性机制和临床影响.
- 评估当前的管理策略,并确定未来的研究需求,以预防和治疗与ifosfamide相关的损伤.
主要方法:
- 对来自Scielo,Scopus和EMBASE数据库的100篇文章进行了全面的文献审查.
- 分析的重点是ifosfamide的有毒代谢物,它们对管细胞的影响以及患者人口统计数据.
主要成果:
- 伊福斯法米德诱导的脏毒性与有毒代谢物如阿克罗莱因和甲有关,导致线粒体损伤和氧化应激.
- 审查发现死亡率为13%,并强调缺乏完全有效的预防策略.
- 目前的干预措施包括水分和强制性尿液,长期监测功能至关重要.
结论:
- 伊福斯法米德在癌症治疗中仍然至关重要,但其毒性带来了诊断和管理的挑战,常常由联合使用的药物加剧.
- 需要进一步的研究来制定有效的预防策略,并确定ifosfamide诱导的毒性早期风险因素.
- 新兴的疗法有望减少ifosfamide诱导的损伤的发生率和严重程度,需要多学科的方法.
相关概念视频
01:11Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
215
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
215
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
168
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
168
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K